ES2020011A6 - Metodo de sintesis de composiciones que comprenden al menos un butano fenolico. - Google Patents

Metodo de sintesis de composiciones que comprenden al menos un butano fenolico.

Info

Publication number
ES2020011A6
ES2020011A6 ES8801751A ES8801751A ES2020011A6 ES 2020011 A6 ES2020011 A6 ES 2020011A6 ES 8801751 A ES8801751 A ES 8801751A ES 8801751 A ES8801751 A ES 8801751A ES 2020011 A6 ES2020011 A6 ES 2020011A6
Authority
ES
Spain
Prior art keywords
pharmaceutical compositions
catecholic butane
skin
treatment
catecholic butanes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES8801751A
Other languages
English (en)
Inventor
Edward S Neiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Block Drug Co Inc
Original Assignee
Chemex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemex Pharmaceuticals Inc filed Critical Chemex Pharmaceuticals Inc
Publication of ES2020011A6 publication Critical patent/ES2020011A6/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

METODO DE SINTESIS DE COMPOSICIONES QUE COMPRENDEN AL MENOS UN BUTANO FENOLICO. CONSISTE EN HACER REACCIONAR UN COMPUESTO DE FORMULA
ES8801751A 1987-06-03 1988-06-03 Metodo de sintesis de composiciones que comprenden al menos un butano fenolico. Expired - Lifetime ES2020011A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/057,481 US5008294A (en) 1985-02-11 1987-06-03 Methods of treating tumors with compositions of catecholic butanes

Publications (1)

Publication Number Publication Date
ES2020011A6 true ES2020011A6 (es) 1991-07-16

Family

ID=22010825

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8801751A Expired - Lifetime ES2020011A6 (es) 1987-06-03 1988-06-03 Metodo de sintesis de composiciones que comprenden al menos un butano fenolico.

Country Status (9)

Country Link
US (1) US5008294A (es)
EP (1) EP0297733A3 (es)
JP (1) JPS6479112A (es)
KR (1) KR970009883B1 (es)
AU (2) AU1736088A (es)
CA (1) CA1334170C (es)
ES (1) ES2020011A6 (es)
IL (1) IL86554A0 (es)
ZA (1) ZA883957B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4235911A1 (de) * 1992-10-23 1994-04-28 Asta Medica Ag Stabilisierte Hexadecylphosphocholinlösungen in Glycerinalkylethern
DE4307976A1 (de) * 1993-03-15 1994-09-22 Beiersdorf Ag Neue Verwendung von Aknemitteln
US5409690A (en) * 1993-06-23 1995-04-25 Chemex Pharmaceuticals, Inc. Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol
EP0750496A1 (en) * 1994-03-14 1997-01-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
US6365787B1 (en) 1994-09-30 2002-04-02 The Johns Hopkins University Compounds for the suppression of HIV TAT transactivation
US5627187A (en) * 1995-04-12 1997-05-06 Katz; Bruce E. 5-FU for treating actinic kerotoses
US5827898A (en) * 1996-10-07 1998-10-27 Shaman Pharmaceuticals, Inc. Use of bisphenolic compounds to treat type II diabetes
KR19990069211A (ko) * 1998-02-05 1999-09-06 성재갑 타이로시나제 저해활성을 갖는 신규 폴리하이드록시-디페닐알칸유도체 및 그의 제조방법
FR2785804B1 (fr) * 1998-11-17 2002-10-18 Sederma Sa Compositions a usage cosmetique ou dermopharmaceutique contenant un extrait de larrea divaricata ou de larrea tridentata pour ralentir le vieillissement cutane
US6608108B2 (en) * 1999-10-15 2003-08-19 Johns Hopkins University Method for treatment of tumors using nordihydroguaiaretic acid derivatives
US6214874B1 (en) * 1999-10-15 2001-04-10 John Hopkins University Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N
FR2830195B1 (fr) * 2001-10-03 2004-10-22 Sederma Sa Compositions cosmetiques et dermopharmaceutiques pour les peaux a tendance acneique
US20040156799A1 (en) * 2002-06-04 2004-08-12 Zigang Dong Cancer treatment method and compositions
FI20021184A (fi) 2002-06-19 2003-12-20 Hormos Nutraceutical Oy Ltd Lignaanivalmisteita
JP2007500229A (ja) * 2003-05-20 2007-01-11 ジョンズ・ホプキンズ・ユニバーシティ 腫瘍の治療のためのカテコールブタンの投与のための方法と組成物
US20060141029A1 (en) * 2003-05-20 2006-06-29 Erimos Pharmaceuticals Llc Methods and compositions for delivery of catecholic butanes for treatment of diseases
US7728036B2 (en) * 2003-05-20 2010-06-01 Erimos Pharmaceuticals, Llc Methods for delivery of catecholic butanes for treatment of tumors
KR100567431B1 (ko) 2004-01-08 2006-04-04 황재관 리그난계 화합물을 유효성분으로 함유하는 여드름 치료 또는 예방용 조성물
NZ548740A (en) * 2004-01-30 2010-06-25 Medivir Ab HCV NS-3 Serine protease inhibitors
US7420105B2 (en) 2004-03-11 2008-09-02 Carlsberg A/S Barley for production of flavor-stable beverage
CN100440843C (zh) * 2004-05-12 2008-12-03 华为技术有限公司 一种环网及其业务实现方法
PL1748767T3 (pl) 2004-05-28 2012-08-31 Unigen Inc 1-(3-metylo-2,4-dimetoksyfenylo)-3-(2',4'-dihydroksyfenylo)-propan jako silny inhibitor tyrozynazy
US8440648B2 (en) * 2004-07-20 2013-05-14 Erimos Pharmaceuticals Llc Methods and compositions for treatment of intraepithelial neoplasia
WO2006014669A2 (en) * 2004-07-20 2006-02-09 Erimos Pharmaceuticals Llc Methods and compositions for treatment of intraepithelial neoplasia
US20080096967A1 (en) * 2005-01-27 2008-04-24 Erimos Pharmaceuticals Llc Formulations for Injection of Catecholic Butanes, Including Ndga Compounds, Into Animals
WO2007101111A2 (en) * 2006-02-23 2007-09-07 Erimos Pharmaceuticals Llc Methods of treating influenza viral infections
US8178527B2 (en) * 2006-10-02 2012-05-15 Erimos Pharmaceuticals Llc Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
US9067875B2 (en) 2006-10-02 2015-06-30 Erimos Pharmaceuticals Llc Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
US7824698B2 (en) * 2007-02-02 2010-11-02 Nereus Pharmaceuticals, Inc. Lyophilized formulations of Salinosporamide A
US7946439B1 (en) 2007-04-09 2011-05-24 Tech Serv LLC Protective steel membrane system and method of erection for secondary containment for an above ground storage tank
EP4046619A1 (en) 2008-07-21 2022-08-24 Unigen, Inc. Series of skin-whitening (lightening) compounds
KR20100011963A (ko) * 2008-07-25 2010-02-03 국립암센터 Ｎｄｇａ를 포함하는 트란스글루타미나제 억제용 조성물
MX2011004824A (es) * 2008-11-07 2012-01-12 Triact Therapeutics Inc Uso de derivados de butano catecólico en terapia contra el cáncer.
US8586799B2 (en) 2011-03-24 2013-11-19 Unigen, Inc. Compounds and methods for preparation of diarylpropanes
AU2014223548A1 (en) 2013-02-26 2015-10-15 Triact Therapeutics, Inc. Cancer therapy
WO2015035410A1 (en) 2013-09-09 2015-03-12 Triact Therapeutic, Inc. Cancer therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3934034A (en) * 1972-08-21 1976-01-20 Sandoz, Inc. Hydroxy substituted diphenylalkyls for treatment of lipidemia
US4895727A (en) * 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
US4695590A (en) * 1986-05-05 1987-09-22 California Health Technologies Method for retarding aging

Also Published As

Publication number Publication date
CA1334170C (en) 1995-01-31
EP0297733A2 (en) 1989-01-04
IL86554A0 (en) 1988-11-15
AU2099092A (en) 1992-10-08
US5008294A (en) 1991-04-16
KR970009883B1 (en) 1997-06-19
JPS6479112A (en) 1989-03-24
EP0297733A3 (en) 1990-12-05
AU1736088A (en) 1988-12-08
KR890000092A (ko) 1989-03-11
ZA883957B (en) 1989-02-22

Similar Documents

Publication Publication Date Title
ES2020011A6 (es) Metodo de sintesis de composiciones que comprenden al menos un butano fenolico.
EP0288534A4 (en) COMPOSITIONS OF CATECHOLIC BUTANES WITH ZINC.
US5091171B2 (en) Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
ATE214933T1 (de) Dermatologische zusammensetzungen, welche benzylneroxid und ein mittel zur verminderung von hautreizungen enthalten
DE3568272D1 (en) 4-vinylbenzoic-acid derivatives, their preparation and their use as therapeutical compositions and as ligands
DE69429822D1 (de) Abschuppende zusammensetzung von salicylsäure und zwitterionischen verbindungen
ES2147780T3 (es) Compuestos sinteticos afines al extracto de corteza de roble, y procedimiento para utilizar los mismos.
ATE33635T1 (de) Substituierte sulfonamidbenzamide, antiarythmische mittel und deren zusammensetzungen.
FR2782269B1 (fr) Composition cosmetique et/ou dermatologique contenant de l'acide salicylique ou un derive d'acide salicylique et son utilisation
WO1994011010B1 (en) Compositions of oak bark extract, related synthetic compositions, and method of using same
AU6857887A (en) Therapeutic agent
MX9805705A (es) Compuestos biaromaticos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
CA2157836A1 (en) L-carnitine salt and cosmetic and pharmaceutical compositions containing same for treating dermatoses
NZ334593A (en) Use of zinc salts of conjugated linoleic acids to treat skin disorders particularly eczema, psoriasis and dermatitis and their use in the treatment of skin cancer
CA2322878A1 (en) Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
ES2137125A1 (es) La utilizacion de la sal de zinc del acido glicirretico en preparados contra el acne y las composiciones que contienen dicha sal.
EP0311616A4 (en) COMBINATION OF GAMMA INTERFERON AND ANTI-FLAMMING AGENTS OR ANTIPYRETIC AGENTS FOR THE TREATMENT OF DISEASES.
AU604418B2 (en) Cosmetic composition
GR852793B (es)
DK0700897T3 (da) L-carnitinsalt og kosmetiske og farmaceutiske præparater indeholdende samme til behandling af hudsygdomme
BR9300017A (pt) Composicao cosmetica ou dermatologica
DE69007051D1 (de) Mittel zur kosmetischen oder pharmazeutischen Verwendung.
JPS568309A (en) White cosmetic
EP0968707A3 (de) Gegen Akne und entzündete Comedonen wirksame Zubereitungen enthaltend Serin-Proteasen und ein oder mehrere Calciumsalze
IT8519907A0 (it) Prodotto farmaceutico cosmetico, in particolare per la cura di acne e seborrea.

Legal Events

Date Code Title Description
PC1A Transfer granted

Owner name: BLOCK DRUG COMPANY INC.

FD1A Patent lapsed

Effective date: 20080604